Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab - PubMed (original) (raw)
Comparative Study
. 2017 Sep;134(2):325-330.
doi: 10.1007/s11060-017-2528-3. Epub 2017 Jun 19.
Affiliations
- PMID: 28631191
- DOI: 10.1007/s11060-017-2528-3
Comparative Study
Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab
Victor A Levin et al. J Neurooncol. 2017 Sep.
Abstract
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM). Of the 1186 glioma patients who received chemotherapy ASI exposure improved OS (HR 0.82; 95% CI 0.71, 0.93; p = 0.003). When stratified by BEV exposure, a sub-analysis revealed further OS advantage for the BEV group (HR 0.75, 95% CI 0.62, 0.90; p = 0.002). In a second cohort of 181 rGBM patients who received BEV in varying dosages, ASI exposure conferred an OS advantage (HR 0.649; 95% CI 0.46, 0.92; p = 0.016). Moreover, patients with ASI exposure who received low-dose BEV treatment (AUCBEV < 3.6 mg wk/kg) had a significantly longer OS (median = 99 weeks; 95% CI 44.3, 205) than those without ASI (median OS = 55.6 weeks; 95% CI 37.7-73.7; p = 0.032). ASI use is associated with longer OS in glioma patients. Further survival advantage with ASI use was observed in rGBM patients receiving low-dose bevacizumab. These data warrant prospective evaluation of adding ASI to low-dose BEV treatment in GBM patients to improve the outcome of standard therapies.
Keywords: Angiotensin receptor blockers; Avastin; Bevacizumab; Drug dose; Glioblastoma; Glioma; Retrospective analysis.
Similar articles
- Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
Levin VA, Mendelssohn ND, Chan J, Stovall MC, Peak SJ, Yee JL, Hui RL, Chen DM. Levin VA, et al. J Neurooncol. 2015 Mar;122(1):145-50. doi: 10.1007/s11060-014-1693-x. Epub 2015 Jan 11. J Neurooncol. 2015. PMID: 25575937 - Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD, Bhamidipati D, Song A, Eldredge-Hindy HB, Siglin J, Dan TD, Champ CE, Zhang I, Bar-Ad V, Kim L, Glass J, Evans JJ, Andrews DW, Werner-Wasik M, Shi W. Palmer JD, et al. J Neurooncol. 2018 Dec;140(3):623-628. doi: 10.1007/s11060-018-2989-z. Epub 2018 Sep 4. J Neurooncol. 2018. PMID: 30182159 - Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS. Jakobsen JN, et al. J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12. J Neurooncol. 2018. PMID: 29330749 - Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis.
Chen Y, Guo L, Li X, Liu R, Ren C, Du S. Chen Y, et al. Clin Neurol Neurosurg. 2020 Nov;198:106239. doi: 10.1016/j.clineuro.2020.106239. Epub 2020 Sep 20. Clin Neurol Neurosurg. 2020. PMID: 33007724 Review. - Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
Tipping M, Eickhoff J, Ian Robins H. Tipping M, et al. J Clin Neurosci. 2017 Oct;44:101-106. doi: 10.1016/j.jocn.2017.06.070. Epub 2017 Jul 12. J Clin Neurosci. 2017. PMID: 28711289 Free PMC article. Review.
Cited by
- Targeting the tumour vasculature: from vessel destruction to promotion.
Guelfi S, Hodivala-Dilke K, Bergers G. Guelfi S, et al. Nat Rev Cancer. 2024 Aug 29. doi: 10.1038/s41568-024-00736-0. Online ahead of print. Nat Rev Cancer. 2024. PMID: 39210063 Review. - Metformin synergizes with PD-1 blockade to promote normalization of tumor vessels via CD8T cells and IFNγ.
Tokumasu M, Nishida M, Zhao W, Chao R, Imano N, Yamashita N, Hida K, Naito H, Udono H. Tokumasu M, et al. Proc Natl Acad Sci U S A. 2024 Jul 23;121(30):e2404778121. doi: 10.1073/pnas.2404778121. Epub 2024 Jul 17. Proc Natl Acad Sci U S A. 2024. PMID: 39018197 - Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, Pineda B, Gutiérrez-Arroyo JL, Loras A, Gonzalez-Bonet LG, Martinez-Cadenas C, Estrela JM, Marqués-Torrejón MÁ. Obrador E, et al. Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529. Int J Mol Sci. 2024. PMID: 38473776 Free PMC article. Review. - Alleviating hypoxia to improve cancer immunotherapy.
Fan P, Zhang N, Candi E, Agostini M, Piacentini M; TOR Centre; Shi Y, Huang Y, Melino G. Fan P, et al. Oncogene. 2023 Dec;42(49):3591-3604. doi: 10.1038/s41388-023-02869-2. Epub 2023 Oct 26. Oncogene. 2023. PMID: 37884747 Review. - Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.
Shafqat A, Omer MH, Ahmed EN, Mushtaq A, Ijaz E, Ahmed Z, Alkattan K, Yaqinuddin A. Shafqat A, et al. Front Immunol. 2023 Jul 3;14:1200941. doi: 10.3389/fimmu.2023.1200941. eCollection 2023. Front Immunol. 2023. PMID: 37520562 Free PMC article. Review.
References
- J Gastroenterol Hepatol. 2015 Nov;30(11):1643-50 - PubMed
- Anticancer Drugs. 2013 Jan;24(1):90-7 - PubMed
- Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64 - PubMed
- Br J Cancer. 2005 Apr 11;92(7):1247-52 - PubMed
- Nat Commun. 2013;4:2516 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical